TAO Synergies TAOX
NASDAQ TAOX
$4.12 +0.11 (+2.74%)
As of: Sep 9, 2026 · 12:29 PM EDT

TAO Synergies (TAOX) Other Non-Current Liabilities (2021 - 2026)

TAO Synergies' (TAOX) quarterly Other Non-Current Liabilities came in at $2.8 million in Q2 2026, up 268.22% on a YoY basis from $752000.0 in Q2 2025, and down 26.43% quarter-over-quarter from $3.8 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Other Non-Current Liabilities for 6 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Liabilities rose 268.22% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (up 268.22% YoY), and the FY2025 full-year result was $2.1 million, down 65.78% from the prior year.
  • Other Non-Current Liabilities retreated to $2.8 million in Q2 2026 per TAOX's latest filing, from $3.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $6.3 million in Q1 2025 and bottomed at $141000.0 in Q1 2024.
  • Historically, Other Non-Current Liabilities has averaged $2.5 million across 5 years, with a median of $1.7 million in 2023.
  • The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities slumped 91.02% in 2024, then soared 4336.88% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $1.5 million in 2022, then declined by 26.29% to $1.1 million in 2023, then jumped by 454.99% to $6.2 million in 2024, then plunged by 65.78% to $2.1 million in 2025, then jumped by 30.98% to $2.8 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2.8 million, $3.8 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.50 Bn 197.51 Bn 7.24 Bn
2 Gilead Sciences 181.29 Bn 178.11 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.55 Bn 74.56 Bn 3.93 Bn
5 Argenx Se 61.65 Bn 56.47 Bn 1.37 Bn
6 Moderna 54.65 Bn 49.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.18 Bn 30.87 Bn 992.69 Mn
8 Biogen 31.36 Bn 30.07 Bn 1.96 Bn
9 Roivant Sciences 30.01 Bn 30.01 Bn 1.16 Mn
10 TAO Synergies 30.79 Mn 30.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.77 Mn
Mar 31, 2026 3.76 Mn
Dec 31, 2025 2.11 Mn
Sep 30, 2025 646,000.00
Jun 30, 2025 752,000.00
Mar 31, 2025 6.26 Mn
Dec 31, 2024 6.18 Mn
Sep 30, 2024 6.12 Mn
Jun 30, 2024 236,000.00
Mar 31, 2024 141,000.00
Dec 31, 2023 1.11 Mn
Sep 30, 2023 1.66 Mn
Jun 30, 2023 2.63 Mn
Mar 31, 2023 922,000.00
Dec 31, 2022 1.51 Mn
Dec 31, 2021 9.90 Mn